Rescinding NOT-HG-20-041 “NHGRI Late Application Policy for NHGRI-Specific FOAs with Application Due Dates in May, June, and July” and Clarifying the Late Application Receipt Dates of NHGRI-Specific FOAs
Notice Number:
NOT-HG-20-042

Key Dates

Release Date:

June 1, 2020

Related Announcements

NOT-HG-20-041 - NHGRI Late Application Policy for NHGRI-Specific FOAs with Application Due Dates in May, June, and July

PAR-20-100 - Genomic Community Resources (U24)

RFA-HG-20-014 -Novel Synthetic Nucleic Acid Technology Development (R01) (Clinical Trial not Allowed)

RFA-HG-20-015 - Novel Synthetic Nucleic Acid Technology Development (R21) (Clinical Trial not Allowed)

RFA-HG-20-019 - NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed)

PAR-19-204 - Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional)

RFA-HG-18-001 - Novel Nucleic Acid Sequencing Technology Development (R01 Clinical Trial Not Allowed)

RFA-HG-18-002 - Novel Nucleic Acid Sequencing Technology Development (R21 Clinical Trial Not Allowed)

RFA-HG-18-003 - Novel Nucleic Acid Sequencing Technology Development (R43/R44 Clinical Trial Not Allowed)

RFA-HG-20-001 - Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry-Study Sites (U01 Clinical Trial Not Allowed)

RFA-HG-20-002 - Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry-Coordinating Center (U01 Clinical Trial Not Allowed)

RFA-HG-20-016 - Novel Synthetic Nucleic Acid Technology Development (R43/R44) ­(Clinical Trial not Allowed)

Issued by

National Human Genome Research Institute (NHGRI)

Purpose

The purpose of this Notice is to rescind NOT-HG-20-041 and to clarify the end of the late application window for NHGRI specific RFAs and PARs due in May, June, and July 2020. Late applications will be accepted by 5:00 PM local time up to two weeks after the application due date for the NHGRI-specific FOAs listed below. Institutions do not need to request advance permission. A cover letter from the institution is not required to take advantage of this flexibility. NIH’s late application submission policy for institutions closed due to the effects of COVID-19 (NOT-OD-20-082) still applies to these FOAs for institutions that are not able to submit within the two-week window. However, note that late applications submitted per NOT-OD-20-082 are considered on a case-by-case basis.

Title of FOA

FOA number

Applicable Application Due Date (All Applications)

Late Applications Accepted by the Following Date

Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional)

PAR-19-204

May 18, 2020

June 1, 2020

Genomic Community Resources (U24)

PAR-20-100

May 25, 2020

June 8, 2020

Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry – Study Sites (U01 Clinical Trial Not Allowed)

RFA-HG-20-001

June 23, 2020

July 7, 2020

Polygenic Risk Score (PRS) Methods and Analysis for Populations of Diverse Ancestry – Coordinating Center (U01 Clinical Trial Not Allowed)

RFA-HG-20-002

June 23, 2020

July 7, 2020

Novel Synthetic Nucleic Acid Technology Development (R01 Clinical Trial not allowed)

RFA-HG-20-014

June 24, 2020

July 8, 2020

Novel Synthetic Nucleic Acid Technology Development (R21) (Clinical Trial not allowed)

RFA-HG-20-015

June 24, 2020

July 8, 2020

Novel Synthetic Nucleic Acid Technology Development (R43/R44) (Clinical Trial Not Allowed)

RFA-HG-20-016

June 24, 2020

July 8, 2020

NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed)

RFA-HG-20-019

June 24, 2020

July 8, 2020

Novel Nucleic Acid Sequencing Technology Development (R01 Clinical Trial Not Allowed)

RFA-HG-18-001

June 26, 2020

July 10, 2020

Novel Nucleic Acid Sequencing Technology Development (R21 Clinical Trial Not Allowed)

RFA-HG-18-002

June 26, 2020

July 10, 2020

Novel Nucleic Acid Sequencing Technology Development (R43/R44 Clinical Trial Not Allowed)

RFA-HG-18-003

June 26, 2020

July 10, 2020

All other FOAs will follow the standard NIH late application policies, including considerations related to the emergency declaration for COVID-19 (NOT-OD-20-082)

Inquiries

Please direct all inquiries to:

Bettie J. Graham, Ph.D.
National Human Genome Research Institute (NHGRI)
Telephone: 301-496-7531
Email: bettie_gra


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices